Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Allergy Therapeutics
AGYAllergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom. Address: Dominion Way, Worthing, United Kingdom, BN14 8SA
Analytics
Preço Alvo de Wall Street
1 004.35 GBXRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave AGY
Análise de Dividendos AGY
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos AGY
Avaliação de ações AGY
Relatório AGY
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |